Antibody Response to Pneumococcal Vaccines PPV and PCV in Beta Thalassemia Major without Spleen

Antibody Response to Pneumococcal Vaccines, Polysaccharides 23 Valence (PPV) and Conjugates 7 Valence (PCV) in Beta Thalassemia Major without Spleen

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

IRCT

Registry ID

IRCT201110116660N3

Enrollment

Registered

2011-11-20

Start date

2011-07-27

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Beta Thalassemia Major. Beta thalassaemia

Interventions

Intervention 1: PPV vaccine, once, 0.5 cc. Intervention 2: PCV vaccine, once, 0.5 cc.

Prevention

PPV vaccine, once, 0.5 cc

PCV vaccine, once, 0.5 cc

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Inclusion Criteria: Splenectomized Thalassemia Major Patients who have not received Pneumococcal Vaccine or have received it more than 5 years ago. Exclusions Criteria: Tthalassemia Major with Spleen.

Exclusion criteria

Exclusion criteria:

Design outcomes

Secondary

Measure	Time frame
Along Diseases. Timepoint: After of study. Method of measurement: Laboratory Test.	—

Primary

Measure	Time frame
Antibody response to pneumococcal vaccines ppv. Timepoint: Evaluation of IgG eight weeks after vaccination. Method of measurement: Laboratory Test.;Antibody response to pneumococcal vaccines pcv. Timepoint: Evaluation of IgG three months after vaccination. Method of measurement: Laboratory Test.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactDr Javad Ghafari

Mazandaran University of Medical Sciences

javad.neg@yahoo.com , ghafari@mazums.ac.ir+98 981512233011

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026